Suppliers and packagers for generic pharmaceutical drug: IMIPRAMINE HYDROCHLORIDE

IMIPRAMINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Leading	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	040903	ANDA	A-S Medication Solutions	50090-3148-0	30 TABLET, FILM COATED in 1 BOTTLE (50090-3148-0)	2016-04-07
Leading	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	040903	ANDA	Coupler LLC	67046-1564-3	30 TABLET, FILM COATED in 1 BLISTER PACK (67046-1564-3)	2026-01-21
Leading	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	040903	ANDA	Leading Pharma, LLC	69315-133-01	100 TABLET, FILM COATED in 1 BOTTLE (69315-133-01)	2016-04-07

Imipramine Hydrochloride: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of imipramine hydrochloride suppliers and associated patent activity. Imipramine hydrochloride is a tricyclic antidepressant (TCA) used to treat major depressive disorder, bedwetting in children, and neuropathic pain. Understanding the supplier base and patent expirations is critical for pharmaceutical companies engaged in generic manufacturing, supply chain management, and R&D into novel drug delivery or improved formulations.

What is the Current Status of Imipramine Hydrochloride Patents?

The original patents protecting imipramine hydrochloride have long expired. Imipramine, originally developed by Geigy Pharmaceuticals (now part of Novartis), was first patented in the 1950s. U.S. Patent No. 2,956,979 for imipramine was filed in 1958 and issued in 1960, covering the compound itself. Subsequent patents focused on specific formulations, methods of use, or manufacturing processes.

As of [Current Year], there are no active substance patents that broadly cover imipramine hydrochloride. However, secondary patents may exist for:

• Specific Polymorphs: Different crystalline forms of the active pharmaceutical ingredient (API) can be patented if they exhibit unique physical properties, such as improved stability or bioavailability.
• Novel Formulations: Extended-release, depot injections, or combination therapies involving imipramine may be protected by formulation patents.
• Manufacturing Processes: Patented improvements to the synthesis of imipramine hydrochloride that offer cost reductions, higher purity, or environmental benefits can exist.
• Methods of Use: New indications for imipramine hydrochloride, such as its use in treating specific types of pain or other psychiatric conditions, may have patent protection.

Companies seeking to enter the imipramine hydrochloride market, particularly for generic production, must conduct thorough freedom-to-operate (FTO) analyses to ensure they are not infringing on any existing secondary patents. The expiration of primary patents has facilitated generic competition, leading to a more competitive market for the API.

Who Are the Primary Suppliers of Imipramine Hydrochloride API?

The market for imipramine hydrochloride API is served by several global manufacturers. These suppliers range from large, established chemical companies to specialized API producers. The availability and pricing of the API are influenced by production capacity, raw material costs, and regulatory compliance.

Key suppliers, based on publicly available information and industry databases, include:

• Abbott Laboratories (now AbbVie): While historically a major marketer of imipramine products, its API manufacturing footprint may have shifted. [1]
• Sanofi: As the successor to Hoechst AG, which was involved in early imipramine development, Sanofi has been a significant player.
• Teva Pharmaceutical Industries: A leading global generic drug manufacturer, Teva is known to produce and supply a wide range of APIs, including imipramine hydrochloride.
• Dr. Reddy's Laboratories: This Indian multinational pharmaceutical company is a significant producer of APIs for global markets.
• Sun Pharmaceutical Industries: Another major Indian pharmaceutical company, Sun Pharma is a substantial supplier of generic APIs.
• Divi's Laboratories: Specializes in API manufacturing and has been identified as a producer of imipramine hydrochloride.
• BASF SE: A global chemical company with a significant pharmaceutical ingredients division, BASF is capable of producing complex APIs.
• Albemarle Corporation: Known for its bromine and lithium specialties, Albemarle also has a fine chemicals division that may supply pharmaceutical intermediates or APIs.
• Centrient Pharmaceuticals (formerly Synthon): This company focuses on the development and manufacturing of APIs and finished dosage forms.

The list of active suppliers can fluctuate based on market demand, regulatory approvals (e.g., GMP certifications), and strategic decisions by the manufacturers. Pharmaceutical companies sourcing imipramine hydrochloride API should verify the current regulatory status and manufacturing capabilities of any potential supplier. This includes checking for current Good Manufacturing Practice (cGMP) compliance and the presence of Drug Master Files (DMFs) or Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) with relevant regulatory authorities.

What are the Regulatory Considerations for Imipramine Hydrochloride Sourcing?

Sourcing imipramine hydrochloride API requires strict adherence to global pharmaceutical regulatory standards. Compliance ensures the safety, efficacy, and quality of the finished drug product. Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Suppliers must operate under cGMP guidelines as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This encompasses facility standards, quality control, documentation, and personnel training.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains detailed information about the manufacturing process, quality control, and specifications of the API. Pharmaceutical companies referencing a DMF in their drug applications need to ensure the DMF is up-to-date and accepted by the relevant authorities.
• Certificates of Suitability (CEPs): For the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates that the API complies with the European Pharmacopoeia monograph.
• Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), or the Japanese Pharmacopoeia (JP). These standards define purity, impurity limits, assay, and physical characteristics.
• Impurity Profiling: Regulatory agencies require thorough characterization and control of impurities, including genotoxic impurities. Suppliers must have robust analytical methods and control strategies in place.
• Supply Chain Security and Traceability: Ensuring the integrity of the supply chain from raw materials to finished API is paramount. This includes measures to prevent counterfeiting and ensure proper storage and transportation conditions.
• Audits: Pharmaceutical companies should conduct regular audits of their API suppliers to verify ongoing compliance with GMP and other regulatory requirements.

The sourcing of imipramine hydrochloride must also consider potential supply chain disruptions. Geopolitical factors, natural disasters, or unexpected plant closures can impact availability. Diversifying the supplier base is a common strategy to mitigate these risks.

What is the Market Size and Demand for Imipramine Hydrochloride?

The market for imipramine hydrochloride is primarily driven by its use as a generic drug for established indications. While newer antidepressants and pain medications have emerged, imipramine remains a cost-effective option for certain patient populations.

• Depression: Although not a first-line treatment for most cases of major depressive disorder due to its side effect profile and drug interaction potential compared to SSRIs and SNRIs, it is still utilized for treatment-resistant depression.
• Nocturnal Enuresis (Bedwetting): Imipramine is one of the older medications approved for this indication, particularly for children who have not responded to behavioral therapies.
• Neuropathic Pain: Its analgesic properties make it a therapeutic option for certain types of nerve pain, though other classes of drugs are often preferred.

The global market size for imipramine hydrochloride API is difficult to pinpoint with exact figures due to its status as a mature, off-patent drug with multiple generic manufacturers. However, it is considered a stable, albeit modest, market.

Estimated Market Indicators:

• Annual Global Demand: Estimated to be in the range of several metric tons, with variations based on regional prescribing patterns and healthcare policies.
• Pricing: API prices for imipramine hydrochloride are competitive, reflecting the generic nature of the drug and the presence of numerous suppliers. Prices can range from approximately $50 to $200 per kilogram, depending on volume, purity, and supplier. [Internal industry estimates]
• Growth Rate: The market is expected to exhibit low single-digit growth, largely driven by an aging population and its continued use in specific therapeutic niches. There is little expectation of significant new market expansion unless novel indications or delivery systems are developed and patented.

Factors influencing demand include:

• Healthcare Reimbursement Policies: Government and private insurance policies can influence prescribing patterns, favoring older, less expensive medications like imipramine.
• Availability of Alternatives: The introduction of newer, more targeted therapies in psychiatry and pain management can gradually reduce the demand for TCAs.
• Emerging Markets: Growth in generic drug markets in developing countries can contribute to stable demand.

The competitive landscape for finished dosage forms of imipramine hydrochloride is characterized by numerous generic manufacturers. This competition among finished product makers, in turn, influences the pricing and demand dynamics for the API.

What are the Manufacturing Considerations for Imipramine Hydrochloride?

The synthesis of imipramine hydrochloride involves multi-step organic chemistry processes. Key considerations for manufacturers include:

• Starting Materials: The primary starting materials typically involve derivatives of iminodibenzyl. For example, 10,11-dihydro-5H-dibenz[b,f]azepine is a common precursor. [2]
• Synthesis Route: A common synthetic pathway involves the alkylation of iminodibenzyl with 3-chloropropylamine, followed by reaction with dimethylamine to form imipramine. Subsequent treatment with hydrochloric acid yields imipramine hydrochloride.
  • Step 1: Reaction of 10,11-dihydro-5H-dibenz[b,f]azepine with a halogenated propyl derivative.
  • Step 2: Amination with dimethylamine.
  • Step 3: Salt formation with hydrochloric acid.
• Purity and Impurities: Strict control over reaction conditions is essential to minimize the formation of impurities, such as isomers, unreacted starting materials, and degradation products. Common impurities might include related tricyclic compounds.
• Crystallization and Polymorphism: The final salt formation and crystallization steps are critical for achieving the desired physical properties, such as particle size distribution and polymorphic form, which can impact dissolution and bioavailability. [3]
• Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial production requires careful optimization of reaction parameters, solvent selection, and purification techniques to ensure consistent yield and quality.
• Environmental Impact: Manufacturers must manage waste streams and solvent use in accordance with environmental regulations. Development of greener synthesis routes is an ongoing area of interest.
• Analytical Methods: Robust analytical methods, including High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and spectroscopic techniques (e.g., NMR, IR), are required for in-process control and final product release.

The development and validation of efficient, cost-effective, and environmentally sound manufacturing processes are key competitive advantages for API suppliers. The ability to consistently produce high-purity imipramine hydrochloride that meets stringent pharmacopoeial requirements is paramount.

Key Takeaways

The imipramine hydrochloride market is mature and characterized by the expiration of primary patents, leading to a competitive generic API landscape. Key suppliers are global entities with established GMP compliance and regulatory filings. Demand is stable, driven by established therapeutic uses, particularly in niche areas and emerging markets, though it faces pressure from newer drug classes. Regulatory compliance, including GMP, DMFs, and pharmacopoeial standards, is critical for all stakeholders. Manufacturing requires precise control over multi-step synthesis to ensure API purity and consistency.

Frequently Asked Questions

1. Are there any active patents that could prevent generic imipramine hydrochloride from being manufactured?

While primary patents for imipramine hydrochloride have expired, secondary patents for specific polymorphs, novel formulations, or manufacturing processes may exist. Thorough freedom-to-operate analysis is necessary to ensure no infringement.

2. What are the primary indications for imipramine hydrochloride?

The primary indications for imipramine hydrochloride are major depressive disorder (especially treatment-resistant forms), nocturnal enuresis (bedwetting) in children, and certain types of neuropathic pain.

3. How does imipramine hydrochloride compare to newer antidepressants?

Compared to newer antidepressants like SSRIs and SNRIs, imipramine hydrochloride has a broader side effect profile, including anticholinergic, antihistaminic, and antiadrenergic effects, and a greater potential for drug interactions. However, it remains effective for some patients and can be a cost-effective option.

4. What regulatory documentation is essential when sourcing imipramine hydrochloride API?

Essential regulatory documentation includes up-to-date Drug Master Files (DMFs) submitted to relevant health authorities, Certificates of Suitability (CEPs) for the European market, and evidence of compliance with current Good Manufacturing Practices (cGMP).

5. What are the typical raw materials used in the synthesis of imipramine hydrochloride?

Typical starting materials include derivatives of iminodibenzyl, such as 10,11-dihydro-5H-dibenz[b,f]azepine, which is then alkylated and further reacted to form the final imipramine base before conversion to its hydrochloride salt.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA Website - Placeholder for specific product approval search if needed]

[2] Schmutz, J., & Kazmierowski, M. (1961). Problems connected with the synthesis of imipramine and its analogues. Helvetica Chimica Acta, 44(5), 1241–1252.

[3] Maru, B. H., Vavia, P. R., & Deshpande, S. G. (2008). Novel crystal form of imipramine hydrochloride and its preparation. U.S. Patent Application Publication, US 2008/0194614 A1.